Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor
Catalogue Number: 591640-USB
| Manufacturer: | United States Biological |
| Type: | Recombinant Monoclonal |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug, 1 mg |
| Host name: | Human |
| Clone: | |
| Isotype: | IgG1, kappa |
| Immunogen: | Recombinant human abciximab biosimilar produced in mammalian cells. |
| Application: | ELISA, NT |
Description
Description: Abciximab Biosimilar uses the same protein sequences as the therapeutic antibody abciximab. Abciximab, a glycoprotein IIb/IIIa receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor. While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
Additional Text
Antibody Clonality
Recombinant Monoclonal
591640 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations